149 related articles for article (PubMed ID: 34880877)
21. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of TGF-β signalling in combination with nal-IRI plus 5-Fluorouracil/Leucovorin suppresses invasion and prolongs survival in pancreatic tumour mouse models.
Hong E; Park S; Ooshima A; Hong CP; Park J; Heo JS; Lee S; An H; Kang JM; Park SH; Park JO; Kim SJ
Sci Rep; 2020 Feb; 10(1):2935. PubMed ID: 32076068
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of trastuzumab combined with SOX or IP chemotherapy regimen in the treatment of advanced gastric cancer.
Xu D; Zhang Z; Zhang S; Fang X; Wang L; Li Q
J BUON; 2021; 26(3):932-939. PubMed ID: 34268956
[TBL] [Abstract][Full Text] [Related]
24. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.
Bonnet E; Mastier C; Lardy-Cléaud A; Rochefort P; Sarabi M; Guibert P; Cattey-Javouhey A; Desseigne F; de La Fouchardière C
Curr Oncol; 2019 Aug; 26(4):e466-e472. PubMed ID: 31548814
[TBL] [Abstract][Full Text] [Related]
26. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
27. BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
Kondo T; Kanai M; Matsubara J; Quy PN; Fukuyama K; Yamamoto Y; Yamada T; Nishigaki M; Minamiguchi S; Takeda M; Nishio K; Matsumoto S; Muto M
Pancreas; 2020; 49(10):e101-e103. PubMed ID: 33017331
[No Abstract] [Full Text] [Related]
28. Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
Pazderová N; Urbán V; Makovník M; Macák D; Janega P; Chovanec M; Rejleková K; Mardiak J; Mego M
Klin Onkol; 2020; 33(3):220-225. PubMed ID: 32683879
[TBL] [Abstract][Full Text] [Related]
29. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy.
Katsuda M; Miyazawa M; Ojima T; Katanuma A; Hakamada K; Sudo K; Asahara S; Endo I; Ueno M; Hara K; Yamada S; Fujii T; Satoi S; Ioka T; Ohira M; Akahori T; Kitano M; Nagano H; Furukawa M; Adachi T; Yamaue H
Trials; 2019 Apr; 20(1):242. PubMed ID: 31029154
[TBL] [Abstract][Full Text] [Related]
30. Initial experience with neoadjuvant FOLFIRINOX as first line therapy for locally advanced pancreatic cancer.
Karachaliou GS; Lazarou V; Giannis D; Astras G; Moris D; Petrou A
J BUON; 2020; 25(5):2525-2527. PubMed ID: 33277879
[TBL] [Abstract][Full Text] [Related]
31. Phase II Study of Preoperative Chemoradiotherapy With S-1 Plus Oxaliplatin for Locally Advanced Rectal Cancer (PerSeUS-RC01).
Matsuhashi N; Takahashi T; Tanaka C; Yawata K; Yamada M; Iwata Y; Kiyama S; Mizutani C; Tajima JY; Ishihara T; Yoshida K
Anticancer Res; 2021 Dec; 41(12):6247-6257. PubMed ID: 34848480
[TBL] [Abstract][Full Text] [Related]
32. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
Kawamoto Y; Nakatsumi H; Harada K; Muranaka T; Ishiguro A; Kobayashi Y; Hayashi H; Yuki S; Sawada K; Yagisawa M; Nakano S; Sakamoto N; Komatsu Y
Oncologist; 2021 Oct; 26(10):e1675-e1682. PubMed ID: 34050586
[TBL] [Abstract][Full Text] [Related]
33. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
[TBL] [Abstract][Full Text] [Related]
34. Predicting the chemosensitivity of pancreatic cancer cells as a personalized therapy.
Rudno-Rudzińska J; Michel O; Płochocki M; Kulbacka J
Adv Clin Exp Med; 2022 Sep; 31(9):1049-1053. PubMed ID: 36135813
[TBL] [Abstract][Full Text] [Related]
35. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
[TBL] [Abstract][Full Text] [Related]
36. Modified FOLFOX6 with oxaliplatin stop-and-go strategy and oral S-1 maintenance therapy in advanced colorectal cancer: CCOG-0704 study.
Nakayama G; Kodera Y; Yokoyama H; Okuda N; Watanabe T; Tanaka C; Iwata N; Ohashi N; Koike M; Fujiwara M; Nakao A
Int J Clin Oncol; 2011 Oct; 16(5):506-11. PubMed ID: 21431344
[TBL] [Abstract][Full Text] [Related]
37. Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
Cao C; Parikh P; Moezardalan K; Anantharaman A; Azarm A; Lai J
Anticancer Res; 2020 Jul; 40(7):4029-4032. PubMed ID: 32620648
[TBL] [Abstract][Full Text] [Related]
38. SMAD4 and NF1 mutations as potential biomarkers for poor prognosis to cetuximab-based therapy in Chinese metastatic colorectal cancer patients.
Mei Z; Shao YW; Lin P; Cai X; Wang B; Ding Y; Ma X; Wu X; Xia Y; Zhu D; Shu Y; Fu Z; Gu Y
BMC Cancer; 2018 Apr; 18(1):479. PubMed ID: 29703253
[TBL] [Abstract][Full Text] [Related]
39. Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer.
Byun Y; Han Y; Kang JS; Choi YJ; Kim H; Kwon W; Kim SW; Oh DY; Lee SH; Ryu JK; Kim YT; Jang JY
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):416-425. PubMed ID: 31218836
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostics and therapy of pancreatic carcinoma].
Wenzel P; von Figura G
Dtsch Med Wochenschr; 2021 Feb; 146(4):246-252. PubMed ID: 33592660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]